Drug Development

JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?
Silvio Danese, Marjorie Argollo, Catherine Le Berre, Laurent Peyrin-Biroulet

Gut Oct 2019, 68 (10) 1893-1899; DOI: 10.1136/gutjnl-2019-318448
CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells
Gwenola Manic, Michele Signore, Antonella Sistigu, Giorgio Russo, Francesca Corradi, Silvia Siteni, Martina Musella, Sara Vitale, Maria Laura De Angelis, Matteo Pallocca, Carla Azzurra Amoreo, Francesca Sperati, Simone Di Franco, Sabina Barresi, Eleonora Policicchio, Gabriele De Luca, Francesca De Nicola, Marcella Mottolese, Ann Zeuner, Maurizio Fanciulli, Giorgio Stassi, Marcello Maugeri-Saccà, Marta Baiocchi, Marco Tartaglia, Ilio Vitale, Ruggero De Maria

Gut May 2018, 67 (5) 903-917; DOI: 10.1136/gutjnl-2016-312623
Vonoprazan, aspirin and NSAIDs: new era in acid inhibition and gastroprotection
Ali S Taha

Gut Jun 2018, 67 (6) 995-996; DOI: 10.1136/gutjnl-2017-315252
Next generation of small molecules in inflammatory bowel disease
Pablo Olivera, Silvio Danese, Laurent Peyrin-Biroulet

Gut Feb 2017, 66 (2) 199-209; DOI: 10.1136/gutjnl-2016-312912
Caffeine protects against experimental acute pancreatitis by inhibition of inositol 1,4,5-trisphosphate receptor-mediated Ca²⁺ release
Wei Huang, Matthew C Cane, Rajarshi Mukherjee, Peter Szatmary, Xiaoying Zhang, Victoria Elliott, Yulin Ouyang, Michael Chvanov, Diane Latawiec, Li Wen, David M Booth, Andrea C Haynes, Ole H Petersen, Alexei V Tepikin, David N Criddle, Robert Sutton

Gut Feb 2017, 66 (2) 301-313; DOI: 10.1136/gutjnl-2015-309363
APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma
David S H Liu, Matthew Read, Carleen Cullinane, Walid J Azar, Christina M Fennell, Karen G Montgomery, Sue Haupt, Ygal Haupt, Klas G Wiman, Cuong P Duong, Nicholas J Clemons, Wayne A Phillips

Gut Oct 2015, 64 (10) 1506-1516; DOI: 10.1136/gutjnl-2015-309770
A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis
Paul J Rutgeerts, Richard N Fedorak, Daan W Hommes, Andreas Sturm, Daniel C Baumgart, Brian Bressler, Stefan Schreiber, John C Mansfield, Marna Williams, Meina Tang, Jennifer Visich, Xiaohui Wei, Mary Keir, Diana Luca, Dimitri Danilenko, Jackson Egen, Sharon O'Byrne

Gut Aug 2013, 62 (8) 1122-1130; DOI: 10.1136/gutjnl-2011-301769
Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver
Ibrahim M Sayed, Lieven Verhoye, Laurence Cocquerel, Florence Abravanel, Lander Foquet, Claire Montpellier, Yannick Debing, Ali Farhoudi, Czeslaw Wychowski, Jean Dubuisson, Geert Leroux-Roels, Johan Neyts, Jacques Izopet, Thomas Michiels, Philip Meuleman

Gut May 2017, 66 (5) 920-929; DOI: 10.1136/gutjnl-2015-311109
Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice
Niu Shi, Nobuhiko Hiraga, Michio Imamura, C Nelson Hayes, Yizhou Zhang, Keiichi Kosaka, Akihito Okazaki, Eisuke Murakami, Masataka Tsuge, Hiromi Abe, Hiroshi Aikata, Shoichi Takahashi, Hidenori Ochi, Chise Tateno-Mukaidani, Katsutoshi Yoshizato, Hirotaka Matsui, Akinori Kanai, Toshiya Inaba, Fiona McPhee, Min Gao, Kazuaki Chayama

Gut Jul 2013, 62 (7) 1055-1061; DOI: 10.1136/gutjnl-2012-302600
Monocyte-derived hepatocyte-like cells for causality assessment of idiosyncratic drug-induced liver injury
Andreas Benesic, Alexandra Leitl, Alexander L Gerbes

Gut Sep 2016, 65 (9) 1555-1563; DOI: 10.1136/gutjnl-2015-309528

Main menu

Drug Development

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Drug Development

Pages